These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 10421233)
1. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Tessier D; Maheux P; Khalil A; Fülöp T Metabolism; 1999 Jul; 48(7):897-903. PubMed ID: 10421233 [TBL] [Abstract][Full Text] [Related]
2. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Lawrence JM; Reid J; Taylor GJ; Stirling C; Reckless JP Diabetes Care; 2004 Jan; 27(1):41-6. PubMed ID: 14693964 [TBL] [Abstract][Full Text] [Related]
3. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Betteridge DJ; Vergès B Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of efficacy and tolerability of gliclazide and metformin combination: a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin. Pareek A; Chandurkar N; Zawar S; Agrawal N Am J Ther; 2010; 17(6):559-65. PubMed ID: 20093927 [TBL] [Abstract][Full Text] [Related]
5. Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes. Vilar L; Canadas V; Arruda MJ; Arahata C; Agra R; Pontes L; Montenegro L; Vilar CF; Silva LM; Albuquerque JL; Gusmão A Arq Bras Endocrinol Metabol; 2010 Mar; 54(3):311-8. PubMed ID: 20520962 [TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Belcher G; Lambert C; Edwards G; Urquhart R; Matthews DR Diabetes Res Clin Pract; 2005 Oct; 70(1):53-62. PubMed ID: 16002175 [TBL] [Abstract][Full Text] [Related]
7. Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes. Al-Azzam SI; Alomari M; Khader YS; Almahasneh FA; Muflih SM; Altawalbeh S Endocr Res; 2012; 37(1):7-11. PubMed ID: 21977974 [TBL] [Abstract][Full Text] [Related]
8. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P; Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663 [TBL] [Abstract][Full Text] [Related]
9. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Matthews DR; Charbonnel BH; Hanefeld M; Brunetti P; Schernthaner G Diabetes Metab Res Rev; 2005; 21(2):167-74. PubMed ID: 15386821 [TBL] [Abstract][Full Text] [Related]
10. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy. Habib SS; Aslam M; Naveed AK; Razi MS Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671 [TBL] [Abstract][Full Text] [Related]
11. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Ceriello A; Johns D; Widel M; Eckland DJ; Gilmore KJ; Tan MH Diabetes Care; 2005 Feb; 28(2):266-72. PubMed ID: 15677777 [TBL] [Abstract][Full Text] [Related]
12. [The efficacy and safety of 30 mg slow-released-gliclazide in type 2 diabetes mellitus]. Li GW; Pan CY; Gao Y; Yuan SY; Yang WY; Xing XY; Tian H; Guo XH; Li HB Zhonghua Nei Ke Za Zhi; 2004 Jul; 43(7):510-4. PubMed ID: 15312405 [TBL] [Abstract][Full Text] [Related]
13. The effect of short-term glycemic regulation with gliclazide and metformin on postprandial lipemia. Emral R; Köseoğlulari O; Tonyukuk V; Uysal AR; Kamel N; Corapçioğlu D Exp Clin Endocrinol Diabetes; 2005 Feb; 113(2):80-4. PubMed ID: 15772898 [TBL] [Abstract][Full Text] [Related]
15. [Gliclazide and metformin combination in patients with type 2 diabetes. Preliminary data]. Galeone F; Fiore G; Arcangeli A; Mannucci E Minerva Endocrinol; 1998 Sep; 23(3):71-5. PubMed ID: 10063324 [TBL] [Abstract][Full Text] [Related]
16. Genetic cause of hyperglycaemia and response to treatment in diabetes. Pearson ER; Starkey BJ; Powell RJ; Gribble FM; Clark PM; Hattersley AT Lancet; 2003 Oct; 362(9392):1275-81. PubMed ID: 14575972 [TBL] [Abstract][Full Text] [Related]
17. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide. Jennings PE; Belch JJ Metabolism; 2000 Feb; 49(2 Suppl 1):23-6. PubMed ID: 10693916 [TBL] [Abstract][Full Text] [Related]
18. Is gliclazide a sulfonylurea with difference? A review in 2016. Singh AK; Singh R Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475 [TBL] [Abstract][Full Text] [Related]
19. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Erem C; Ozbas HM; Nuhoglu I; Deger O; Civan N; Ersoz HO Exp Clin Endocrinol Diabetes; 2014 May; 122(5):295-302. PubMed ID: 24710641 [TBL] [Abstract][Full Text] [Related]
20. A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes. McAlpine LG; McAlpine CH; Waclawski ER; Storer AM; Kay JW; Frier BM Eur J Clin Pharmacol; 1988; 34(2):129-32. PubMed ID: 3289948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]